Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
grade B 20.36 2.98% 0.59
EXEL closed up 2.98 percent on Friday, May 24, 2019, on 68 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Up
See historical EXEL trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
Fell Below 200 DMA Bearish 2.98%
Fell Below 20 DMA Bearish 2.98%
Multiple of Ten Bearish Other 2.98%
200 DMA Support Bullish -0.73%
Up 3 Days in a Row Strength -0.73%
Crossed Above 200 DMA Bullish -0.34%
Crossed Above 20 DMA Bullish -0.34%

Older signals for EXEL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Chemistry Biotechnology Cancer Treatment Of Cancer Cyclopropanes Sanofi Tyrosine Kinase Inhibitors Genentech Protein Kinase Inhibitor Metastatic Castration Resistant Prostate Cancer Small Molecule Therapies
Is EXEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.31
52 Week Low 13.42
Average Volume 3,086,016
200-Day Moving Average 20.0981
50-Day Moving Average 21.8656
20-Day Moving Average 19.8915
10-Day Moving Average 19.719
Average True Range 0.7679
ADX 25.85
+DI 17.277
-DI 23.6537
Chandelier Exit (Long, 3 ATRs ) 18.6163
Chandelier Exit (Short, 3 ATRs ) 21.1037
Upper Bollinger Band 20.9299
Lower Bollinger Band 18.8531
Percent B (%b) 0.73
BandWidth 10.44064
MACD Line -0.4425
MACD Signal Line -0.6384
MACD Histogram 0.1959
Fundamentals Value
Market Cap 5.99 Billion
Num Shares 294 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 101.80
Price-to-Sales 23.83
Price-to-Book 51.23
PEG Ratio 2.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.28
Resistance 3 (R3) 21.19 20.80 21.12
Resistance 2 (R2) 20.80 20.57 20.84 21.07
Resistance 1 (R1) 20.58 20.42 20.69 20.67 21.02
Pivot Point 20.19 20.19 20.25 20.23 20.19
Support 1 (S1) 19.97 19.96 20.08 20.06 19.70
Support 2 (S2) 19.58 19.81 19.62 19.65
Support 3 (S3) 19.36 19.58 19.60
Support 4 (S4) 19.45